<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669695</url>
  </required_header>
  <id_info>
    <org_study_id>0721</org_study_id>
    <secondary_id>2007-005286-35</secondary_id>
    <nct_id>NCT00669695</nct_id>
  </id_info>
  <brief_title>Systemic Inflammation and Obstructive Sleep Apnea Syndrome: Effect of Atorvastatin</brief_title>
  <acronym>StatinflaSAS</acronym>
  <official_title>Systemic Inflammation and Obstructive Sleep Apnea Syndrome: Effect of Atorvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trial is to evaluate the effect of Atorvastatin on the endothelial
      function improvement during the obstructive sleep apnea syndrome (OSAS) after 3 months of
      treatment, by a double-blind, randomized, placebo-controlled, multi-center study.

      An interim analysis will be performed when 25 patients per group will be included.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives of this clinical trial :

        -  To evaluate the effect of Atorvastatin in comparison with the placebo on the
           inflammation occurring during OSAS, after 3 months of treatment.

        -  To evaluate the effect of Atorvastatin in comparison with the placebo on the
           insulin-resistance associated to OSAS, after 3 months of treatment.

        -  To evaluate the effect of Atorvastatin in comparison with the placebo on the
           hypercholesterolemia associated to OSAS, after 3 months of treatment.

        -  To evaluate at 6 months, the effect of the continuous positive airway pressure (CPAP) +
           Atorvastatin association on the previously cited parameters, in comparison with
           Atorvastatin, CPAP and placebo.

        -  To measure the CPAP efficiency in comparison with sham CPAP in patients receiving the
           placebo, after 3 months of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis performed without efficient results
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the percent of peripheral arterial tone (PAT) improvement in comparison with the baseline situation.</measure>
    <time_frame>after 3 months of Atorvastatin treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the inflammation occurring during OSAS.</measure>
    <time_frame>after 3 months of Atorvastatin or placebo treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the insulin-resistance associated to OSAS.</measure>
    <time_frame>after 3 months of Atorvastatin or placebo treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the hypercholesterolemia associated to OSAS.</measure>
    <time_frame>after 3 months of Atorvastatin or placebo treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of continuous positive airway pressure (CPAP) + Atorvastatin association on the previously cited parameters, in comparison with effect of Atorvastatin, CPAP and placebo.</measure>
    <time_frame>after 6 months of treatments</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the CPAP efficiency in comparison with sham CPAP in patients receiving the placebo.</measure>
    <time_frame>after 3 months of treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>Stat/CPAP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin and CPAP treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stat/sham CPAP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin and sham CPAP treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/CPAP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo and CPAP treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/sham CPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo and sham CPAP treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin treatment</intervention_name>
    <description>Atorvastatin treatment: tablets of 40 mg Atorvastatin will be administered orally, respecting the dosage of 40 mg/day, for 6 months.</description>
    <arm_group_label>Stat/CPAP</arm_group_label>
    <arm_group_label>Stat/sham CPAP</arm_group_label>
    <other_name>statin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CPAP device</intervention_name>
    <description>This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.</description>
    <arm_group_label>Stat/CPAP</arm_group_label>
    <arm_group_label>Placebo/CPAP</arm_group_label>
    <other_name>positive air way pressure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham CPAP treatment</intervention_name>
    <description>This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.</description>
    <arm_group_label>Stat/sham CPAP</arm_group_label>
    <arm_group_label>Placebo/sham CPAP</arm_group_label>
    <other_name>sham CPAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women &gt; 18 years old

          -  Subjects diagnosed with OSAS (apnea/hypopnea index = AHI &gt; 30/h)

          -  Subjects with clinical ATH from grade I or II controlled with mono-therapy(140&lt;SAP&lt;180
             mmHg and 90&lt;DAP&lt;110 mmHg)

        Exclusion Criteria:

          -  Patients with a history of prior stroke or coronary ischemic disease

          -  Chronic respiratory disease (PaO2 &lt; 60 mmHg and/or PaCO2 &gt; 45 mmHg)

          -  Lung disease

          -  Hypothyroidism

          -  Statin treatment

          -  Antihypertensive treatment with more than one drug

          -  Pregnant or lactating women

          -  Alcohol consumption &gt; 3 units/day

          -  Treatment by itraconazole, ketoconazole, antiprotease, fibrates, antivitamin K,
             diltiazem, verapamil, erythromycin, clarithromycin, cyclosporin.

          -  Hypersensitivity to one of the drug compounds

          -  Patients with modified concomitant treatments during the 3 months before inclusion

          -  Potentially dangerous sleepiness

          -  Jobs at risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis PEPIN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Grenoble, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitary Hospital of Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Annemasse</name>
      <address>
        <city>Annemasse</city>
        <zip>74017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitary Hospital of Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Bergeron C, Kimoff J, Hamid Q. Obstructive sleep apnea syndrome and inflammation. J Allergy Clin Immunol. 2005 Dec;116(6):1393-6.</citation>
    <PMID>16337480</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2008</study_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>statins</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>Obstructive sleep apnea syndrome (OSAS) patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

